Institutional investors purchased a net $16.8 million shares of INSM during the quarter ended September 2017 and now own 97.25% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 2.6 Million shares of Insmed Inc
JANUS CAPITAL MANAGEMENT LLC Bought 2.3 Million shares of Insmed Inc
FIDELITY MANAGEMENT & RESEARCH C... Bought 2.1 Million shares of Insmed Inc